Home › Upcoming votes › AngioDynamics, Inc.
The deadline as the proxy statement states it: “voting instructions in the Notice of Annual Meeting no later than 11:59 p.m., New York City Time, on November 9, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGARAngioDynamics, Inc.: past votes
Ballot read from the proxy statement and checked. As listed in AngioDynamics, Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | ELECTION OF DIRECTORS Director election |
Board | For | 2 nominees; support 96% to 97% |
| 2 | RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Auditor |
Board | For | 99.5% support |
| 3 | ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS Say on pay |
Board | For | 93% support |
| 4 | APPROVAL OF AN AMENDMENT TO THE ANGIODYNAMICS, INC. 2020 EQUITY INCENTIVE PLAN | Board | For | — |
From AngioDynamics, Inc.’s Form 8-K, filed November 12, 2025, for the meeting held November 10, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: James C. Clemmer | 97% | Elected |
| Elect Director: Michael E. Tarnoff, MD | 96% | Elected |
| 2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the f | 99.5% | Approved |
| 3. The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers | 93% | Approved |
The five managers that reported the most shares voted at AngioDynamics, Inc.’s November 10, 2025 meeting, from their Form N-PX filings. This is how they voted then; it says nothing about how they will vote this time. Every manager’s vote.
| Item | BlackRock | Vanguard | Point72 | ARMISTICE CAPITAL, LLC | SYSTEMATIC FINANCIAL MANAGEMENT LP |
|---|---|---|---|---|---|
| Elect Director: James C. Clemmer | For | For | — | — | — |
| Elect Director: Michael E. Tarnoff, MD | For | For | — | — | — |
| 2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accou | For | For | — | — | — |
| 3. The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers | For | For | For | For | For |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.